本文選題：兒童　切入點(diǎn)：青少年　出處：《南京醫(yī)科大學(xué)學(xué)報(bào)(自然科學(xué)版)》2017年11期 　論文類型：期刊論文

【摘要】：目的:總結(jié)分析兒童、青少年非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)臨床特征、預(yù)后因素、化療方案及療效。方法:選取南京醫(yī)科大學(xué)第一附屬醫(yī)院2009年9月—2015年12月收治的68例NHL患者,收集臨床資料,總體生存(overall survival,OS)、無(wú)事件生存(event free survival,EFS)統(tǒng)計(jì)分析用Kaplan-Meier方法,組間生存情況比較用Log-rank檢驗(yàn)。結(jié)果:68例NHL患者中,男45例,女23例,中位年齡17歲(2~20歲);包括成熟B-NHL 33例,NK/T-NHL 22例,淋巴母細(xì)胞淋巴瘤13例。58例化療患者進(jìn)行了生存分析,1年、3年、5年OS率分別為80.7%、70.5%和70.5%,EFS率分別為61.1%、56.3%和56.3%。29例成熟B-NHL接受利妥昔單抗組與未接受利妥昔單抗治療組5年OS率分別為93.3%和66.7%(P=0.038);造血干細(xì)胞移植(hematopoietic stem cell transplantation,HSCT)組與非HSCT組5年EFS率分別為80.0%和46.8%(P=0.050)。患者疾病分期、疾病免疫分型、白蛋白水平與OS有關(guān)(P=0.050)。結(jié)論:兒童、青少年NHL多見(jiàn)于男性,Ⅲ、Ⅳ期比例高,利妥昔單抗靶向治療、HSCT可提高OS和EFS,預(yù)后與疾病分期、免疫分型和白蛋白水平相關(guān)。
[Abstract]:Objective: to summarize and analyze the clinical features, prognostic factors, chemotherapy regimen and curative effect of non-Hodgkin lymphoma NHL in children and adolescents. Methods: 68 patients with NHL were selected from September 2009 to December 2015 in the first affiliated Hospital of Nanjing Medical University. Clinical data were collected, total survival free survival was analyzed by Kaplan-Meier method and Log-rank test was used to compare survival among groups. Results among 68 NHL patients, 45 were male and 23 were female. The median age was 17 years old and 20 years old, including 33 mature B-NHL cases and 22 NKR / T-NHL cases. A survival analysis was conducted in 13 patients with lymphoblastic lymphoma. The OS rates for 1 year, 3 years and 5 years were 80.775% and 70.5%, respectively. The EFS rates were 61.1% and 56.3%, respectively. 29 cases of mature B-NHL received rituximab and no rituximab for 5 years. The EFS rates of hematopoietic stem cell translocation in hematopoietic stem cell transplantation group and non-#en2# group were 80.0% and 46.8% respectively. Conclusion: NHL in children and adolescents is more common in males and higher in stage 鈪，

本文編號(hào)：1575906